Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy

被引：44

作者：

Casado, JL ^{[1
]}

Lopez-Velez, R ^{[1
]}

Pintado, V ^{[1
]}

Quereda, C ^{[1
]}

Antela, A ^{[1
]}

Moreno, S ^{[1
]}

机构：

[1] Hosp Ramon y Cajal, Dept Infect Dis, E-28034 Madrid, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2001年 / 20卷 / 03期

关键词：

D O I：

10.1007/s100960100457

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The aim of this study was to establish the evolution of visceral leishmaniasis (VL) in 10 consecutive patients coinfected with VL and HIV, taking into account the decline in the incidence of opportunistic infections after the introduction of protease inhibitor therapy. During a median follow-up of 31 months, 7 (70%) of 10 patients relapsed. The incidence of relapse was slightly lower than before institution of protease inhibitor therapy (20 vs. 13 patient-months), with a 31% probability that relapse would not have taken place within 2 years. VL relapses occurred even though increases in the CD4+ cell counts were observed and HIV loads were undetectable, suggesting that successful antiretroviral therapy is not sufficient to control the disease. Relapsing patients also had a lower increase in the CD4+ cell count.

引用

页码：202 / 205

页数：4

共 15 条

[1] HIV viral load and response to antileishmanial chemotherapy in co-infected patients [J].

Berhe, N ;

Wolday, D ;

Hailu, A ;

Abraham, Y ;

Ali, A ;

Gebre-Michael, T ;

Desjeux, P ;

Sönnerborg, A ;

Akuffo, H ;

Britton, S .

AIDS, 1999, 13 (14) :1921-1925

[2] CHANGES IN INTERLEUKIN-2 AND INTERLEUKIN-4 PRODUCTION IN ASYMPTOMATIC, HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE INDIVIDUALS [J].

CLERICI, M ;

HAKIM, FT ;

VENZON, DJ ;

BLATT, S ;

HENDRIX, CW ;

WYNN, TA ;

SHEARER, GM .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) :759-765

[3] POTENTIAL ROLE FOR INTERLEUKIN-10 IN THE IMMUNOSUPPRESSION ASSOCIATED WITH KALA-AZAR [J].

HOLADAY, BJ ;

POMPEU, MMD ;

JERONIMO, S ;

TEXEIRA, MJ ;

SOUSA, AD ;

VASCONCELOS, AW ;

PEARSON, RD ;

ABRAMS, JS ;

LOCKSLEY, RM .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2626-2632

[4] INTERFERON-GAMMA AND INTERLEUKIN-4 IN HUMAN LEISHMANIA-DONOVANI INFECTIONS [J].

KEMP, M ;

KURTZHALS, JAL ;

KHARAZMI, A ;

THEANDER, TG .

IMMUNOLOGY AND CELL BIOLOGY, 1993, 71 :583-587

[5] Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? [J].

Kirk, O ;

Lundgren, JD ;

Pedersen, C ;

Nielsen, H ;

Gerstoft, J .

AIDS, 1999, 13 (13) :1647-1651

[6] Treatment of visceral leishmaniasis in HIV-infected patients:: a randomized trial comparing meglumine antimoniate with amphotericin B [J].

Laguna, F ;

López-Vélez, R ;

Pulido, F ;

Salas, A ;

Torre-Cisneros, J ;

Torres, E ;

Medrano, FJ ;

Sanz, J ;

Picó, G ;

Gómez-Rodrigo, J ;

Pasquau, J ;

Alvar, J .

AIDS, 1999, 13 (09) :1063-1069

[7]

LEHN M, 1989, J IMMUNOL, V143, P3020

[8]

LOPEZ JC, 1999, 6 C RETR OPP INF CHI

[9] Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain [J].

Lopez-Velez, R ;

Perez-Molina, JA ;

Guerrero, A ;

Baquero, F ;

Villarrubia, J ;

Escribano, L ;

Bellas, C ;

Perez-Corral, F ;

Alvar, J .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1998, 58 (04) :436-443

[10] Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease [J].

Mezzaroma, I ;

Carlesimo, M ;

Pinter, E ;

Alario, C ;

Sacco, G ;

Muratori, DS ;

Bernardi, ML ;

Paganelli, R ;

Aiuti, F .

AIDS, 1999, 13 (10) :1187-1193

← 1 2 →